Пятый элемент здоровья. Как использовать менструальный цикл для поддержания жизненно важных функций организма - Лиза Хендриксон-Джек

10. Grow, Daniel R., and Khosro Iromloo. “Oral contraceptives maintain a very thin endometrium before operative hysteroscopy.” Fertility and Sterility 85, no. 1 (2006): 204–207; Benagiano, Giuseppe, Alessandra Pera, and Francesco M. Primiero. “The endometrium and hormonal contraceptives.” Human Reproduction 15, no. suppl 1 (2000): 101–118.

11. Hatcher, Robert Anthony, and Anita L. Nelson. (2007). Contraceptive Technology. London: Ardent Media; Nassaralla, Claudia L., Joseph B. Stanford, K. Diane Daly, Mary Schneider, Karen C. Schliep, and Richard J. Fehring. “Characteristics of the menstrual cycle after discontinuation of oral contraceptives.” Journal of Women’s Health 20, no. 2 (2011): 169–177.

12. Oliveira, J.B.A., R.L.R. Baruffi, A.L. Mauri, C.G. Petersen, M.C. Borges, and J.G. Franco. “Endometrial ultrasonography as a predictor of pregnancy in an in-vitro fertilization programme after ovarian stimulation and gonadotrophin-releasing hormone and gonadotrophins.” Human Reproduction 12, no. 11 (1997): 2515–2518; Dickey, Richard P., Terry T. Olar, Steven N. Taylor, David N. Curole, and Ellen M. Matulich. “Relationship of endometrial thickness and pattern to fecundity in ovulation induction cycles: effect of clomiphene citrate alone and with human menopausal gonadotropin.” Fertility and Sterility 59, no. 4 (1993): 756–760.

13. Oliveira, J.B.A., R.L.R. Baruffi, A.L. Mauri, C.G. Petersen, M.C. Borges, and J.G. Franco. “Endometrial ultrasonography as a predictor of pregnancy in an in-vitro fertilization programme after ovarian stimulation and gonadotrophin-releasing hormone and gonadotrophins.” Human Reproduction 12, no. 11 (1997): 2517.

14. Dickey, Richard P., Terry T. Olar, Steven N. Taylor, David N. Curole, and Ellen M. Matulich. “Relationship of endometrial thickness and pattern to fecundity in ovulation induction cycles: effect of clomiphene citrate alone and with human menopausal gonadotropin.” Fertility and Sterility 59, no. 4 (1993): 756–760; Al Mohammady, Maged, Ghada Abdel Fattah, and Mostafa Mahmoud. “The impact of combined endometrial thickness and pattern on the success of intracytoplasmic sperm injection (ICSI) cycles.” Middle East Fertility Society Journal 18, no. 3 (2013): 165–170.

15. Grow, Daniel R., and Khosro Iromloo. “Oral contraceptives maintain a very thin endometrium before operative hysteroscopy.” Fertility and Sterility 85, no. 1 (2006): 204–207; Mascarenhas, Lawrence, Agaath van Beek, H. Coelingh Bennink, and John Newton. “A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK.” Human Reproduction 13, no. 11 (1998): 3059; Benagiano, Giuseppe, Alessandra Pera, and Francesco M. Primiero. “The endometrium and hormonal contraceptives.” Human Reproduction 15, no. suppl 1 (2000): 101–118; Wright, Kristen Page, and Julia V. Johnson. “Evaluation of extended and continuous use oral contraceptives.” Therapeutics and Clinical Risk Management (2008): 905–911.

16. Hidalgo, Maria M., Creusa Hidalgo-Regina, M. Valeria Bahamondes, Ilza Monteiro, Carlos A. Petta, and Luis Bahamondes. “Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel– releasing intrauterine system.” Contraception 80, no. 1 (2009): 84–89; Lakha, F., P.C. Ho, Z.M. Van der Spuy, K. Dada, R. Elton, A.F. Glasier, H.O.D. Critchley, A.R.W. Williams, and D.T. Baird. “A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel).” Human Reproduction 22, no. 9 (2007): 2428–2436.

17. Wright, Kristen Page, and Julia V. Johnson. “Evaluation of extended and continuous use oral contraceptives.” Therapeutics and Clinical Risk Management (2008): 906.

18. Там же, 907.

19. “YAZ (Drospirenone/Ethinyl Estradiol) – Official Website.” Accessed March 18, 2017. www.yaz-us.com

20. Helmerhorst, F.M., J.P. Vandenbroucke, C.J.M. Doggen, and F.R. Rosendaal. “The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.” The BMJ 339 (2009): 1–8.

21. “Thrombosis.” Wikipedia. Accessed August 23, 2017. en.wikipedia.org/wiki/Thrombosis.

22. Hendrickson-Jack, Lisa. “FFP 007 | What the Pill Really Does to Your Hormones | PCOS & Menstrual Irregularities | Dr. Lara Briden.” Fertility Friday Podcast. Podcast Audio, January 30, 2015. fertilityfriday.com/lara

23. Castle, S., and I. Askew. “Contraceptive discontinuation: reasons, challenges, and solutions.” New York: Population Council (2015); 1–33; Berenson, Abbey B., and Constance M. Wiemann. “Contraceptive use among adolescent mothers at 6 months postpartum.” Obstetrics & Gynecology 89, no. 6 (1997): 999–1005; Westhoff, Carolyn L., Stephen Heartwell, Sharon Edwards, Mimi Zieman, Gretchen Stuart, Carrie Cwiak, Anne Davis, Tina Robilotto, Linda Cushman, and Debra Kalmuss. “Oral contraceptive discontinuation: do side effects matter?” American Journal of Obstetrics and Gynecology 196, no. 4 (2007): 412-e1; Peipert, Jeffrey F., Qiuhong Zhao, Jenifer E. Allsworth, Emiko Petrosky, Tessa Madden, David Eisenberg, and Gina Secura. “Continuation and satisfaction of reversible contraception.” Obstetrics and Gynecology 117, no. 5 (2011): 1105.

24. Castle, S., and I. Askew. “Contraceptive discontinuation: reasons, challenges, and solutions.” New York: Population Council (2015); 2–3; Westhoff, Carolyn L., Stephen Heartwell, Sharon Edwards, Mimi Zieman, Gretchen Stuart, Carrie Cwiak, Anne Davis, Tina Robilotto, Linda Cushman, and Debra Kalmuss. “Oral contraceptive discontinuation: do side effects matter?” American Journal of Obstetrics and Gynecology 196, no. 4 (2007): 412e1–412e7.

25. Westfall, John M., Deborah S. Main, and Lynn Barnard. “Continuation rates among injectable contraceptive users.” Family Planning Perspectives (1996): 275–277.

26. Test ID: TTFB Testosterone, Total, Bioavailable, and Free, Serum. TTFB – Clinical: Testosterone, Total, Bioavailable, and Free, Serum. Accessed December 21, 2017. www.mayomedicallaboratories.com/test-catalog/Clinical and Interpretive/83686.

27. Davis, Susan. “Testosterone and sexual desire in women.” Journal of Sex Education and Therapy 25, no. 1 (2000): 25–32.

28. Davis, Susan R., and Jane Tran. “Testosterone influences libido and well being in women.” Trends in Endocrinology & Metabolism 12, no. 1 (2001): 33–37.

29. Zimmerman, Y., M.J.C. Eijkemans, H.J.T. Coelingh Bennink, M.A. Blankenstein, and B.C.J.M. Fauser. “The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis.” Human Reproduction Update 20, no. 1 (2014): 76–105; Crewther, Blair T., Dave Hamilton, Kathleen Casto, Liam P. Kilduff, and Christian J. Cook. “Effects of oral contraceptive use on the salivary testosterone and cortisol responses to training sessions and competitions in elite women athletes.” Physiology & Behavior 147 (2015): 84–90; Greco, Teri, Cynthia A. Graham, John Bancroft, Amanda Tanner, and Helen A. Doll. “The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 μg of ethinyl estradiol.” Contraception 76, no. 1 (2007): 8–17; Biswas, Arijit, Osborne A.C. Viegas, Herjan J.T. Coeling Bennink, Tjeerd Korver, and Shan S. Ratnam. “Effect